Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Current Taxes (2022 - 2025)

BioXcel Therapeutics has reported Current Taxes over the past 4 years, most recently at $32000.0 for Q4 2025.

  • Quarterly results put Current Taxes at $32000.0 for Q4 2025, down 64.84% from a year ago — trailing twelve months through Dec 2025 was $32000.0 (down 64.84% YoY), and the annual figure for FY2025 was $32000.0, down 64.84%.
  • Current Taxes for Q4 2025 was $32000.0 at BioXcel Therapeutics, down from $103000.0 in the prior quarter.
  • Over the last five years, Current Taxes for BTAI hit a ceiling of $529000.0 in Q3 2022 and a floor of $32000.0 in Q4 2025.
  • Median Current Taxes over the past 4 years was $105500.0 (2025), compared with a mean of $154062.5.
  • Biggest five-year swings in Current Taxes: plummeted 74.86% in 2023 and later surged 54.29% in 2025.
  • BioXcel Therapeutics' Current Taxes stood at $82000.0 in 2022, then surged by 41.46% to $116000.0 in 2023, then dropped by 21.55% to $91000.0 in 2024, then plummeted by 64.84% to $32000.0 in 2025.
  • The last three reported values for Current Taxes were $32000.0 (Q4 2025), $103000.0 (Q3 2025), and $108000.0 (Q2 2025) per Business Quant data.